Please assess the completion status of the following clinical trial:

Trial Title: Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mantle cell lymphoma~* Initial immunophenotyping with CD20 and CD5.~* CD20+.~* t (11;14) by karyote, FISH, molecular biology or immunohistochemistry (Bcl-1)~* Patient no previous treated.~* At least one tumor site accessible for assessment~* Aged \> 18 years \< 65~* ECOG \< or = 2.~* No other neoplasms apart from resected basal cell carcinoma or in situ carcinoma.~* signed informed consent~* FEVG 50%~Exclusion Criteria:~* other type of lymphoma~* ECOG \> or = 3~* relapse~* serology VIH + Hepatite +~* diabetis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): observation : 3 years maintenance period with assesments and surveillance every 2 months
- 2 (Type: EXPERIMENTAL): maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance

Based on this trial design, predict the completion outcome and termination type (if applicable).